Persistent corneal epithelial defect

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
S Ophthalmology/ENT (ATC S) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Erythropoietin analogue 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Dompe' Farmaceutici S.p.A. Commercial
    CENEGERMIN; OXYBUPROCAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
    2025-523443-35-00 8 countries n=91
    Pending

Phase II

1 trial
  • Glaukos Corp. Commercial
    LUFEPIRSEN
    2023-507030-24-00 3 countries 2025 n=60
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Glaukos Corp. Commercial 1 Phase II 1
Dompe' Farmaceutici S.p.A. Commercial 1 Phase III 0
New trials by year
2025
1
← All indication landscapes